蛋白质组学技术在妇科疾病研究中的应用

doi:10.3969/j.issn.1674-8115.2021.02.017

摘要/Abstract

摘要：

蛋白质组学是现阶段生物医学研究的核心内容之一。其研究内容涵盖了对信号转导、细胞增殖分化、蛋白质翻译后修饰等生物过程的探索，以及对疾病分子标志物和药物靶标的寻找。该文概述了基于质谱的蛋白质组学技术在妇科常见疾病研究中的应用，包括在多囊卵巢综合征、早发性卵巢功能不全、卵巢癌、子宫内膜癌、宫颈癌的发病机制及生物标志物研究中的应用。

关键词: 蛋白质组学, 多囊卵巢综合征, 早发性卵巢功能不全, 卵巢癌, 子宫内膜癌, 宫颈癌

Abstract:

At present, proteomics is one of the core contents of biomedical research. Its research includes the exploration of biological processes such as signal transduction, cell proliferation and differentiation, protein translation and modification, as well as the search for biomarkers and drug targets of diseases. This review summarizes the application of mass spectrometry-based proteomics to the studies of pathogenesis and biomarkers of common gynecological diseases, including polycystic ovary syndrome, premature ovarian insufficiency, ovarian cancer, endometrial cancer and cervical cancer.

Key words: proteomics, polycystic ovary syndrome, premature ovarian insufficiency, ovarian cancer, endometrial cancer, cervical cancer

中图分类号:

R711.7

黄原昕, 赖东梅. 蛋白质组学技术在妇科疾病研究中的应用[J]. 上海交通大学学报(医学版), 2021, 41(2): 233-240.

Yuan-xin HUANG, Dong-mei LAI. Application of proteomics to the study of gynecological diseases[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 233-240.

图/表 5

参考文献 37

1	Tyers M, Mann M. From genomics to proteomics[J]. Nature, 2003, 422(6928): 193-197.
2	Swiatly A, Plewa S, Matysiak J, et al. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research[J]. J Ovarian Res, 2018, 11(1): 88.
3	Collins BC, Hunter CL, Liu YS, et al. Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry[J]. Nat Commun, 2017, 8(1): 291.
4	Larance M, Lamond AI. Multidimensional proteomics for cell biology[J]. Nat Rev Mol Cell Biol, 2015, 16(5): 269-280.
5	Schwamborn K, Kriegsmann M, Weichert W. MALDI imaging mass spectrometry: from bench to bedside[J]. Biochim Biophys Acta Proteins Proteom, 2017, 1865(7): 776-783.
6	Galazis N, Afxentiou T, Xenophontos M, et al. Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome[J]. Eur J Endocrinol, 2013, 168(2): R33-R43.
7	Ambekar AS, Kelkar DS, Pinto SM, et al. Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development[J]. J Clin Endocrinol Metab, 2015, 100(2): 744-753.
8	Patil K, Yelamanchi S, Kumar M, et al. Quantitative mass spectrometric analysis to unravel glycoproteomic signature of follicular fluid in women with polycystic ovary syndrome[J]. PLoS One, 2019, 14(4): e0214742.
9	Lan CW, Chen MJ, Tai KY, et al. Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling[J]. Sci Rep, 2015, 5: 14994.
10	Amjadi F, Mehdizadeh M, Ashrafi M, et al. Distinct changes in the proteome profile of endometrial tissues in polycystic ovary syndrome compared with healthy fertile women[J]. Reprod Biomed Online, 2018, 37(2): 184-200.
11	Li L, Zhang J, Zeng J, et al. Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome[J]. Int J Mol Med, 2020, 45(5): 1409-1416.
12	Fazilat A, Rashid N, Nigam A, et al. Differential expression of MARK4 protein and related perturbations in females with ovulatory PCOS[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(7): 1064-1074.
13	Arffman RK, Saraswat M, Joenväärä S, et al. Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics[J]. Sci Rep, 2019, 9(1): 17578.
14	Nelson LM. Primary ovarian insufficiency[J]. N Engl J Med, 2009, 360(6): 606-614.
15	Liu X, Wang Y, Zhu P, et al. Human follicular fluid proteome reveals association between overweight status and oocyte maturation abnormality[J]. Clin Proteomics, 2020, 17: 22.
16	Xu M, Che L, Yang Z, et al. Proteomic analysis of fetal ovaries reveals that primordial follicle formation and transition are differentially regulated[J]. Biomed Res Int, 2017, 2017: 6972030.
17	Lee DH, Pei CZ, Song JY, et al. Identification of serum biomarkers for premature ovarian failure[J]. Biochim Biophys Acta Proteins Proteom, 2019, 1867(3): 219-226.
18	Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer[J]. Cell, 2016, 166(3): 755-765.
19	Hüttenhain R, Choi M, Martin de la Fuente L, et al. A targeted mass spectrometry strategy for developing proteomic biomarkers: a case study of epithelial ovarian cancer[J]. Mol Cell Proteomics, 2019, 18(9): 1836-1850.
20	Dieters-Castator DZ, Rambau PF, Kelemen LE, et al. Proteomics-derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma[J]. Clin Cancer Res, 2019, 25(14): 4309-4319.
21	Curtis M, Kenny HA, Ashcroft B, et al. Fibroblasts mobilize tumor cell glycogen to promote proliferation and metastasis[J]. Cell Metab, 2019, 29(1): 141-155.e9.
22	Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts[J]. Nature, 2019, 569(7758): 723-728.
23	Everest-Dass AV, Briggs MT, Kaur G, et al. N-glycan MALDI imaging mass spectrometry on formalin-fixed paraffin-embedded tissue enables the delineation of ovarian cancer tissues[J]. Mol Cell Proteomics, 2016, 15(9): 3003-3016.
24	Coscia F, Lengyel E, Duraiswamy J, et al. Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer[J]. Cell, 2018, 175(1): 159-170.e16.
25	Zhang SF, Wang XY, Fu ZQ, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer[J]. Autophagy, 2015, 11(2): 225-238.
26	Njoku K, Chiasserini D, Whetton AD, et al. Proteomic biomarkers for the detection of endometrial cancer[J]. Cancers, 2019, 11(10): 1572.
27	Martinez-Garcia E, Lopez-Gil C, Campoy I, et al. Advances in endometrial cancer protein biomarkers for use in the clinic[J]. Expert Rev Proteomics, 2018, 15(1): 81-99.
28	Tarney CM, Wang G, Bateman NW, et al. Biomarker panel for early detection of endometrial cancer in the prostate, lung, colorectal, and Ovarian cancer screening trial[J]. Am J Obstet Gynecol, 2019, 221(5): 472.e1-472.e10.
29	Kacírová M, Bober P, Alexovič M, et al. Differential urinary proteomic analysis of endometrial cancer[J]. Physiol Res, 2019, 68(): S483-S490.
30	Mu AK, Lim BK, Aminudin N, et al. Application of SELDI-TOF in N-glycopeptides profiling of the urine from patients with endometrial, ovarian and cervical cancer[J]. Arch Physiol Biochem, 2016, 122(3): 111-116.
31	Martinez-Garcia E, Lesur A, Devis L, et al. Targeted proteomics identifies proteomic signatures in liquid biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment[J]. Clin Cancer Res, 2017, 23(21): 6458-6467.
32	Ceylan Y, Akpınar G, Doger E, et al. Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique[J]. J Gynecol Obstet Hum Reprod, 2020, 49(2): 101652.
33	Tota JE, Ramana-Kumar AV, El-Khatib Z, et al. The road ahead for cervical cancer prevention and control[J]. Curr Oncol, 2014, 21(2): e255-e264.
34	Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis[J]. Lancet Oncol, 2014, 15(2): 172-183.
35	Starodubtseva NL, Brzhozovskiy AG, Bugrova AE, et al. Label-free cervicovaginal fluid proteome profiling reflects the cervix neoplastic transformation[J]. J Mass Spectrom, 2019, 54(8): 693-703.
36	邱峰, 陈富, 刘冬冬, 等. 基于LC-MS/MS筛选宫颈病变和宫颈癌发生和发展过程中的新型蛋白标志物[J]. 南方医科大学学报, 2019, 39(1): 13-22.
37	Padilla-Mendoza JR, Contis-Montes de Oca A, Rodríguez MA, et al. Protein phosphorylation in serine residues correlates with progression from precancerous lesions to cervical cancer in Mexican patients[J]. Biomed Res Int, 2020, 2020: 1-11.

Disease	Sample	Biomarker	Molecular function	Reference
PCOS	Ovarian follicle	Alpha-1-antitrypsin，SERPINA1	Protease inhibitor	[8]
		Inter-alpha-trypsin inhibitor heavy chain 4, ITIH4	Protease inhibitor	[8]
		Mitogen-activated protein kinase kinase 4, MAPKK4	Signal transduction	[9]
	Plasma	Apolipoprotein C3, APOC3	Lipid metabolism	[11]
		Serotransferrin	Iron metabolism	[11]
		Complement C3	Complement activation	[11]
		Properdin	Complement activation	[13]
		Insulin-like growth factor II	Growth factor	[13]

Disease	Sample	Biomarker	Molecular function	Reference
PCOS	Ovarian follicle	Alpha-1-antitrypsin，SERPINA1	Protease inhibitor	[8]
		Inter-alpha-trypsin inhibitor heavy chain 4, ITIH4	Protease inhibitor	[8]
		Mitogen-activated protein kinase kinase 4, MAPKK4	Signal transduction	[9]
	Plasma	Apolipoprotein C3, APOC3	Lipid metabolism	[11]
		Serotransferrin	Iron metabolism	[11]
		Complement C3	Complement activation	[11]
		Properdin	Complement activation	[13]
		Insulin-like growth factor II	Growth factor	[13]

Disease	Sample	Biomarker	Molecular function	Reference
POI	Ovarian follicle	Humanepididymisprotein 4,HE4/WFDC2	Protease inhibitor	[15]
		Reticulocalbin-1/-3, RCN1/RCN3	Calcium-binding protein	[16]
		Heterogeneous nuclear ribonucleoprotein K, HNRNPK	RNA binding protein	[16]
		Actin	Cytoskeleton component	[16]
		Major vault protein, MVP	Nucleo-cytoplasmic transport	[16]
	Plasma	Ceruloplasmin	Copper binding protein	[17]
		Complement C3	Complement activation	[17]
		Fibrinogen α/β	Blood coagulation	[17]
		Sex hormone-binding globulin, SHBG	Steroid binding protein	[17]

Disease	Sample	Biomarker	Molecular function	Reference
POI	Ovarian follicle	Humanepididymisprotein 4,HE4/WFDC2	Protease inhibitor	[15]
		Reticulocalbin-1/-3, RCN1/RCN3	Calcium-binding protein	[16]
		Heterogeneous nuclear ribonucleoprotein K, HNRNPK	RNA binding protein	[16]
		Actin	Cytoskeleton component	[16]
		Major vault protein, MVP	Nucleo-cytoplasmic transport	[16]
	Plasma	Ceruloplasmin	Copper binding protein	[17]
		Complement C3	Complement activation	[17]
		Fibrinogen α/β	Blood coagulation	[17]
		Sex hormone-binding globulin, SHBG	Steroid binding protein	[17]

Disease	Sample	Biomarker	Molecular function	Reference
Ovarian cancer	Tumor tissue	Phosphoglucomutase 1, PGM1	Glycogen metabolism	[21]
		Nicotinamide N-methyltransferase, NNMT	N-methylation	[22]
		Cancer/testis antigen 45, CT45	-	[24]
		Thioredoxin domain-containing protein 17, TXNDC17	-	[25]